Press "Enter" to skip to content

BrainRepair UG | Investment breakthrough for BrainRepair UG start-up – Stem cell therapy for newborns

Dr. Metin Colpan, founding father of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares value EUR 15M

One of essentially the most profitable inventors and entrepreneurs who masterminded the unprecedented success of Qiagen N.V. from a start-up to a 10 billion market cap enterprise has taken the choice to refocus his actions on BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB). BrainRepair UG has developed a singular technique based mostly on personal (autologous) twine blood stem cells to deal with mind injury and cerebral palsy (CP) in newborns affecting 70,000 infants within the EU annually. Metin Colpan’s patented invention has change into a typical technique really helpful by the World Health Organization (WHO) and is utilized by researchers everywhere in the world, altering the way in which they’ll entry, purify and perceive genetic knowledge in DNA and RNA. The European Patent Office states “…The tireless work of German scientist Metin Colpan over four decades has paved the way for rapid and effective genetic data analysis, enabling researchers to better detect disease and unlocking new therapies for conditions, including COVID-19,” and Prof. Dr. Arne Jensen, Co-Founder and CEO of BrainRepair UG, continues “We are delighted that we now can draw on the vast experience Dr. Colpan is offering us as Member of the Board of Directors and Chairman of the Advisory Board on our way to the stock market at Nasdaq First North for which the IPO is planned in November 2021.” BrainRepair UG’s stem cell product has been granted the worldwide first ‘Orphan Drug Designation’ (ODD) by the European Commission and the European Medicines Agency. This designation ensures market exclusivity in all EU member states for 12 years upon market authorisation. Prof. Arne Jensen stresses, “All our personal, scientific, clinical, and philanthropic efforts serve the ultimate goal – to combat infantile Cerebral palsy, the most common disability in childhood, and stop CP in children!”

About Qiagen N.V.
QIAGEN is a German supplier of pattern and assay applied sciences for molecular diagnostics, utilized testing, educational and pharmaceutical analysis. Consolidated below the Dutch holding QIAGEN N.V., the corporate operates greater than 35 workplaces in over 25 nations.[16] QIAGEN’s shares are listed on the NYSE (utilizing ticker QGEN) and on the Frankfurt Stock Exchange within the Prime Standard (utilizing ticker QIA). Thierry Bernard is the corporate’s Chief Executive Officer. The most important operative headquarters are situated in Hilden, Germany. Number of workers: about 5,000. Total fairness: US $2,634.970 million. Industry: Biotechnology. Total property: US $5,748.332 million. Market capitalization: US $ 11,123 billion.

About BrainRepair UG
BrainRepair UG is a medical stage start-up growing leading edge stem cell therapies based mostly on human twine blood for a variety of indications associated to mind harm in youngsters together with these attributable to oxygen lack and irritation (PVL, HIE, NE), hemorrhage, stroke, cerebral palsy (CP), traumatic mind harm (TBI), and spinal twine harm (SCI). BrainRepair UG is the primary Biotech firm worldwide whose stem cell merchandise have been awarded ‘Orphan Medicinal Product Designations’ for the therapy of mind harm in new child infants (PVL, NE) by the European Commission and the European Medicines Agency, EMA. BrainRepair’s Headquarter is in Bochum, Germany. You could go to the web site at https://brainrepair.eu/ for extra info.

Links:
Metin Colpan (DE) – Finalist for the European Inventor Award 2021 – EPO https://www.epo.org/news-events/events/european-inventor/finalists/2021/colpan.html

Autologous Cord Blood Therapy for Infantile Cerebral Palsy: From Bench to Bedside,Obstet Gynecol Int vol.2014,12p; https://www.hindawi.com/journals/ogi/2014/976321/

First Autologous Cord Blood Therapy for Pediatric Ischemic Stroke and Cerebral Palsy Caused by Cephalic Molding throughout Birth: Individual Treatment with Mononuclear Cells”, Case Reports in Transplantation, vol. 2016, Article ID 1717426, 9 pages, 2016. https://www.hindawi.com/journals/crit/2016/1717426/

EMA Orphan medicinal Product Designation Periventricular leukomalacia (PVL): https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161744

EMA Orphan medicinal Product Designation Newborn encephalopathy (NE): https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161743

Contact:
BrainRepair UG (haftungsbeschränkt)
Prof. Dr. med. Arne Jensen, MD, MBA
Ruhr-University Bochum
Campus Clinic Gynaecology
Universitätsstr. 136
44799 Bochum, Germany
Tel.: +49 234 588 196-0
Fax.: +49 234 588 196-19
Email: arne.jensen@brainrepair.eu

Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    %d bloggers like this: